Kamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern Time

NESS ZIONA, Israel–(BUSINESS WIRE)– Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein
therapeutics company focused on orphan indications, announces that it
will release financial results for the first quarter ended March 31,
2016 prior to the open of the U.S. financial markets on Monday, May 9,
2016.

Kamada management will host an investment community conference call on
Monday, May 9, 2016 at 8:30 a.m. Eastern time to discuss these results
and answer questions. Shareholders and other interested parties may
participate in the conference call by dialing 888-803-5993 (from within
the U.S.), 706-634-5454 (from outside the U.S.) and entering the
conference identification number: 5573974. The call will also be webcast
live on the internet on the Company’s website at www.kamada.com.

A replay of the call will be accessible two hours after its completion
through May 15, 2016 by dialing 855-859-2056 (from within the U.S.) or
404-537-3406 (from outside the U.S.) and entering the conference
identification number: 5573974. The call will also be archived for 90
days on the Company’s website at www.kamada.com.

About Kamada

Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan
indications, and has a commercial product portfolio and a robust
late-stage product pipeline. The Company uses its proprietary platform
technology and know-how for the extraction and purification of proteins
from human plasma to produce Alpha-1 Antitrypsin (AAT) in a
highly-purified, liquid form, as well as other plasma-derived Immune
globulins. AAT is a protein derived from human plasma with known and
newly-discovered therapeutic roles given its immunomodulatory,
anti-inflammatory, tissue-protective and antimicrobial properties. The
Company’s flagship product is Glassia®, the first and only liquid,
ready-to-use, intravenous plasma-derived AAT product approved by the
U.S. Food and Drug Administration. Kamada markets Glassia in the U.S.
through a strategic partnership with Baxalta. In addition to Glassia,
Kamada has a product line of seven other pharmaceutical products
administered by injection or infusion, that are marketed through
distributors in more than 15 countries, including Israel, Russia,
Brazil, India and other countries in Latin America and Asia. Kamada has
five late-stage plasma-derived protein products in development,
including an inhaled formulation of AAT for the treatment of AAT
deficiency that its MAA was submitted to the EMA after completing a
pivotal Phase 2/3 clinical trials in Europe and is in Phase 2 clinical
trials in the U.S. and its intravenous AAT to treat type-1 diabetes,
GvHD and to prevent lung transplant rejection. Kamada also leverages its
expertise and presence in the plasma-derived protein therapeutics market
by distributing more than 10 complementary products in Israel that are
manufactured by third parties.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of
Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E
of the U.S. Securities Exchange Act of 1934, as amended, and the safe
harbor provisions of the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements are statements that are not
historical facts, such as statements regarding assumptions and results
related to financial results forecast, commercial results, timing and
results of clinical trials and EMA and U.S. FDA authorizations.
Forward-looking statements are based on Kamada’s current knowledge and
its present beliefs and expectations regarding possible future events
and are subject to risks, uncertainties and assumptions. Actual results
and the timing of events could differ materially from those anticipated
in these forward-looking statements as a result of several factors
including, but not limited to, unexpected results of clinical trials,
delays or denial in the U.S. FDA or the EMA approval process, additional
competition in the AATD market or further regulatory delays. The
forward-looking statements made herein speak only as of the date of this
announcement and Kamada undertakes no obligation to update publicly such
forward-looking statements to reflect subsequent events or
circumstances, except as otherwise required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160504005260/en/